1177 Stock Overview
About the company
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company’s products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Rewards
Risk analysis
No risks detected for 1177 from our risk checks.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.38 |
| 52 Week High | HK$5.39 |
| 52 Week Low | HK$3.58 |
| Beta | 0.54 |
| 1 Month Change | 6.31% |
| 3 Month Change | -0.91% |
| 1 Year Change | -10.43% |
| 3 Year Change | -38.48% |
| 5 Year Change | -36.01% |
| Change since IPO | 16,027.84% |
Recent News & Updates
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Recent updates
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well
Aug 27Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?
Jul 14Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
May 17Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 31% Undervaluation?
Apr 01These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well
Dec 28Insider Buying: The Sino Biopharmaceutical Limited (HKG:1177) Founder & Senior Vice Chairman Just Bought 4.7% More Shares
Dec 10Sino Biopharmaceutical Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Dec 02Sino Biopharmaceutical Limited's (HKG:1177) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 25
Shareholder Returns
| 1177 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.8% | -2.7% | 0.7% |
| 1Y | -10.4% | -10.5% | -5.7% |
Return vs Industry: 1177 matched the Hong Kong Pharmaceuticals industry which returned -10.5% over the past year.
Return vs Market: 1177 underperformed the Hong Kong Market which returned -5.7% over the past year.
Price Volatility
| 1177 volatility | |
|---|---|
| 1177 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 1177 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 1177's weekly volatility (4%) has been stable over the past year.
Sino Biopharmaceutical Limited Fundamentals Summary
| 1177 fundamental statistics | |
|---|---|
| Market Cap | HK$80.19b |
| Earnings (TTM) | HK$9.19b |
| Revenue (TTM) | HK$31.64b |
8.8x
P/E Ratio2.6x
P/S RatioIs 1177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1177 income statement (TTM) | |
|---|---|
| Revenue | CN¥27.70b |
| Cost of Revenue | CN¥5.54b |
| Gross Profit | CN¥22.16b |
| Other Expenses | CN¥14.11b |
| Earnings | CN¥8.05b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Mar 31, 2023
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 80.01% |
| Net Profit Margin | 29.06% |
| Debt/Equity Ratio | 30.0% |
How did 1177 perform over the long term?
See historical performance and comparison